Clinical Trial

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Study acronym: ED-ENVISION
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-07-02; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-01-02
Trial Details
NCT Number NCT06494904
Lead Sponsor Yale University
Collaborators: National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, National Institute on Drug Abuse (NIDA), Alameda Health System
Conditions Opioid Use Disorder
Enrollment 360 participants
Start Date 2024-12-06
Primary Completion 2027-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-28